GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anika Therapeutics Inc (FRA:AKP) » Definitions » Cyclically Adjusted PS Ratio

Anika Therapeutics (FRA:AKP) Cyclically Adjusted PS Ratio : 2.36 (As of Sep. 21, 2024)


View and export this data going back to . Start your Free Trial

What is Anika Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-09-21), Anika Therapeutics's current share price is €22.60. Anika Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 was €9.56. Anika Therapeutics's Cyclically Adjusted PS Ratio for today is 2.36.

The historical rank and industry rank for Anika Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:AKP' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.82   Med: 6.12   Max: 12.12
Current: 2.53

During the past years, Anika Therapeutics's highest Cyclically Adjusted PS Ratio was 12.12. The lowest was 1.82. And the median was 6.12.

FRA:AKP's Cyclically Adjusted PS Ratio is ranked worse than
54.31% of 650 companies
in the Drug Manufacturers industry
Industry Median: 2.315 vs FRA:AKP: 2.53

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Anika Therapeutics's adjusted revenue per share data for the three months ended in Jun. 2024 was €2.625. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €9.56 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Anika Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Anika Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anika Therapeutics Cyclically Adjusted PS Ratio Chart

Anika Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.87 6.37 4.44 3.28 2.31

Anika Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.73 1.92 2.31 2.55 2.51

Competitive Comparison of Anika Therapeutics's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PS Ratio falls into.



Anika Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Anika Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=22.60/9.56
=2.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Anika Therapeutics's adjusted Revenue per Share data for the three months ended in Jun. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=2.625/132.5538*132.5538
=2.625

Current CPI (Jun. 2024) = 132.5538.

Anika Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201409 1.109 100.428 1.464
201412 1.272 99.070 1.702
201503 0.935 99.621 1.244
201506 1.331 100.684 1.752
201509 1.378 100.392 1.819
201512 1.848 99.792 2.455
201603 1.307 100.470 1.724
201606 1.566 101.688 2.041
201609 1.524 101.861 1.983
201612 1.818 101.863 2.366
201703 1.454 102.862 1.874
201706 1.980 103.349 2.540
201709 1.509 104.136 1.921
201712 1.647 104.011 2.099
201803 1.175 105.290 1.479
201806 1.753 106.317 2.186
201809 1.597 106.507 1.988
201812 1.657 105.998 2.072
201903 1.529 107.251 1.890
201906 1.911 108.070 2.344
201909 1.874 108.329 2.293
201912 1.823 108.420 2.229
202003 2.232 108.902 2.717
202006 1.919 108.767 2.339
202009 1.894 109.815 2.286
202012 1.881 109.897 2.269
202103 1.995 111.754 2.366
202106 2.164 114.631 2.502
202109 2.294 115.734 2.627
202112 2.146 117.630 2.418
202203 2.303 121.301 2.517
202206 2.578 125.017 2.733
202209 2.785 125.227 2.948
202212 2.559 125.222 2.709
202303 2.417 127.348 2.516
202306 2.784 128.729 2.867
202309 2.655 129.860 2.710
202312 2.690 129.419 2.755
202403 2.536 131.776 2.551
202406 2.625 132.554 2.625

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anika Therapeutics  (FRA:AKP) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Anika Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Anika Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anika Therapeutics Business Description

Traded in Other Exchanges
Address
32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.